NASDAQ:CDMO Avid Bioservices (CDMO) Stock Forecast, Price & News $9.44 -0.28 (-2.88%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$9.42▼$9.8750-Day Range$9.40▼$13.3252-Week Range$9.18▼$21.05Volume486,572 shsAverage Volume702,686 shsMarket Capitalization$595.76 millionP/E RatioN/ADividend YieldN/APrice Target$20.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Avid Bioservices MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside111.9% Upside$20.00 Price TargetShort InterestBearish8.38% of Shares Sold ShortDividend StrengthN/ASustainability-0.96Upright™ Environmental ScoreNews Sentiment0.89Based on 6 Articles This WeekInsider TradingSelling Shares$394,626 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.14) to $0.13 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector458th out of 972 stocksPharmaceutical Preparations Industry203rd out of 452 stocks 3.3 Analyst's Opinion Consensus RatingAvid Bioservices has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.00, Avid Bioservices has a forecasted upside of 111.9% from its current price of $9.44.Amount of Analyst CoverageAvid Bioservices has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.38% of the outstanding shares of Avid Bioservices have been sold short.Short Interest Ratio / Days to CoverAvid Bioservices has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Avid Bioservices has recently increased by 1.54%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAvid Bioservices does not currently pay a dividend.Dividend GrowthAvid Bioservices does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAvid Bioservices has received a 68.99% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Biopharmaceuticals", "Clinical research services", and "Process engineering services for the pharmaceutical industry" products. See details.Environmental SustainabilityThe Environmental Impact score for Avid Bioservices is -0.96. Previous Next 3.3 News and Social Media Coverage News SentimentAvid Bioservices has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Avid Bioservices this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for CDMO on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows5 people have added Avid Bioservices to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avid Bioservices insiders have sold 107.04% more of their company's stock than they have bought. Specifically, they have bought $190,600.00 in company stock and sold $394,626.00 in company stock.Percentage Held by InsidersOnly 2.39% of the stock of Avid Bioservices is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Avid Bioservices are expected to grow in the coming year, from ($0.14) to $0.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avid Bioservices is -236.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avid Bioservices is -236.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvid Bioservices has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Avid Bioservices (NASDAQ:CDMO) StockAvid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.Read More CDMO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDMO Stock News HeadlinesOctober 1, 2023 | americanbankingnews.comAvid Bioservices, Inc. (NASDAQ:CDMO) Receives $20.00 Consensus Price Target from AnalystsSeptember 30, 2023 | americanbankingnews.comAvid Bioservices (NASDAQ:CDMO) Coverage Initiated by Analysts at William BlairOctober 1, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.September 29, 2023 | msn.comWilliam Blair Initiates Coverage of Avid Bioservices (CDMO) with Market Perform RecommendationSeptember 25, 2023 | americanbankingnews.comJoseph Carleone Acquires 20,000 Shares of Avid Bioservices, Inc. (NASDAQ:CDMO) StockSeptember 23, 2023 | finance.yahoo.comInsider Buying: Director Joseph Carleone Acquires 20,000 Shares of Avid Bioservices Inc (CDMO)September 8, 2023 | finance.yahoo.comQ1 2024 Avid Bioservices Inc Earnings CallSeptember 7, 2023 | seekingalpha.comAvid Bioservices GAAP EPS of -$0.03 misses by $0.01, revenue of $37.7M beats by $1.61MOctober 1, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.September 7, 2023 | finance.yahoo.comAvid Bioservices Reports Financial Results for First Quarter Ended July 31, 2023September 6, 2023 | benzinga.comEarnings Outlook For Avid BioservicesAugust 31, 2023 | finance.yahoo.comAvid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2024 After Market Close on September 7, 2023August 4, 2023 | seekingalpha.comAvid Bioservices Shifts To More Growth Amid Costly Expansion EffortsJuly 6, 2023 | msn.comAvid Bioservices (CDMO) Price Target Decreased by 11.24% to 20.15June 23, 2023 | finance.yahoo.comWhy Avid Bioservices Stock Was Plummeting This WeekJune 22, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Accolade (ACCD), Avid Bioservices (CDMO)June 21, 2023 | seekingalpha.comAvid Bioservices GAAP EPS of $0.00 misses by $0.01, revenue of $39.8M beats by $0.9MJune 21, 2023 | finance.yahoo.comAvid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2023June 20, 2023 | seekingalpha.comAvid Bioservices FQ4 2023 Earnings PreviewJune 14, 2023 | finance.yahoo.comAvid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2023 After Market Close on June 21, 2023June 8, 2023 | finance.yahoo.comShould You Invest in Avid Bioservices (CDMO)?May 3, 2023 | benzinga.comDirector at Avid Bioservices Exercises Options Worth $88KApril 27, 2023 | msn.comIqvia, Icon lag contract research rivals after Q1 earningsApril 24, 2023 | finance.yahoo.comAvid Bioservices Joins Elite Club Of Stocks With RS Ratings Over 90April 17, 2023 | finance.yahoo.comImproved Earnings Required Before Avid Bioservices, Inc. (NASDAQ:CDMO) Shares Find Their FeetApril 4, 2023 | finance.yahoo.comAvid Bioservices Unveils Completed Mammalian Cell Facilities Expansion Providing Significantly Increased Capacity for Existing and Future CustomersMarch 14, 2023 | msn.comKeybanc Upgrades Avid Bioservices (CDMO)See More Headlines Receive CDMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter. Email Address CDMO Company Calendar Last Earnings9/07/2023Today9/30/2023Next Earnings (Estimated)12/05/2023Fiscal Year End4/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CDMO CUSIPN/A CIK704562 Webwww.avidbio.com Phone(714) 508-6100Fax714-838-5817Employees365Year FoundedN/APrice Target and Rating Average Stock Price Forecast$20.00 High Stock Price Forecast$25.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+111.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$560,000.00 Net Margins-2.06% Pretax Margin-1.96% Return on Equity-1.54% Return on Assets-0.64% Debt Debt-to-Equity Ratio0.75 Current Ratio1.53 Quick Ratio0.90 Sales & Book Value Annual Sales$149.27 million Price / Sales3.99 Cash Flow$0.15 per share Price / Cash Flow63.02 Book Value$3.02 per share Price / Book3.13Miscellaneous Outstanding Shares63,110,000Free Float61,605,000Market Cap$595.76 million OptionableOptionable Beta1.68 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Nicholas Stewart Green B.Sc. (Age 58)MBA, Pres, CEO & Director Comp: $1.35MMr. Daniel R. Hart (Age 50)Chief Financial Officer Comp: $719.75kMr. Richard Richieri (Age 58)Chief Operations Officer Comp: $561.68kMr. Mark R. Ziebell J.D. (Age 59)VP, Gen. Counsel & Corp. Sec. Comp: $647.1kMr. Matthew Kwietniak (Age 54)Chief Commercial Officer Comp: $553.59kMs. Oksana LukashVP of PeopleMore ExecutivesKey CompetitorsKura OncologyNASDAQ:KURATravere TherapeuticsNASDAQ:TVTXBicycle TherapeuticsNASDAQ:BCYCPureTech HealthNASDAQ:PRTCCentessa PharmaceuticalsNASDAQ:CNTAView All CompetitorsInsiders & InstitutionsJoseph CarleoneBought 20,000 shares on 9/21/2023Total: $190,600.00 ($9.53/share)Alberta Investment Management CorpBought 68,449 shares on 8/24/2023Ownership: 0.155%Wolverine Trading LLCBought 26,200 shares on 8/23/2023Ownership: 0.000%California State Teachers Retirement SystemSold 1,641 shares on 8/21/2023Ownership: 0.121%Teachers Retirement System of The State of KentuckyBought 1,086 shares on 8/21/2023Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions CDMO Stock - Frequently Asked Questions Should I buy or sell Avid Bioservices stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CDMO shares. View CDMO analyst ratings or view top-rated stocks. What is Avid Bioservices' stock price forecast for 2023? 3 brokerages have issued 12-month price objectives for Avid Bioservices' shares. Their CDMO share price forecasts range from $15.00 to $25.00. On average, they anticipate the company's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 111.9% from the stock's current price. View analysts price targets for CDMO or view top-rated stocks among Wall Street analysts. How have CDMO shares performed in 2023? Avid Bioservices' stock was trading at $13.77 at the beginning of 2023. Since then, CDMO stock has decreased by 31.4% and is now trading at $9.44. View the best growth stocks for 2023 here. When is Avid Bioservices' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, December 5th 2023. View our CDMO earnings forecast. How were Avid Bioservices' earnings last quarter? Avid Bioservices, Inc. (NASDAQ:CDMO) announced its quarterly earnings results on Thursday, September, 7th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.01. The biopharmaceutical company earned $37.73 million during the quarter, compared to the consensus estimate of $34 million. Avid Bioservices had a negative net margin of 2.06% and a negative trailing twelve-month return on equity of 1.54%. During the same period in the prior year, the business earned $0.02 EPS. What ETFs hold Avid Bioservices' stock? ETFs with the largest weight of Avid Bioservices (NASDAQ:CDMO) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE) and Franklin Genomic Advancements ETF (HELX).Invesco S&P SmallCap Health Care ETF (PSCH). When did Avid Bioservices' stock split? Avid Bioservices shares reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What guidance has Avid Bioservices issued on next quarter's earnings? Avid Bioservices updated its FY 2024 earnings guidance on Thursday, September, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $145.00 million-$165.00 million, compared to the consensus revenue estimate of $155.71 million. What is Roger Lias' approval rating as Avid Bioservices' CEO? 5 employees have rated Avid Bioservices Chief Executive Officer Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among the company's employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 63.0% of employees surveyed would recommend working at Avid Bioservices to a friend. What other stocks do shareholders of Avid Bioservices own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE). What is Avid Bioservices' stock symbol? Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO." How do I buy shares of Avid Bioservices? Shares of CDMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Avid Bioservices' stock price today? One share of CDMO stock can currently be purchased for approximately $9.44. How much money does Avid Bioservices make? Avid Bioservices (NASDAQ:CDMO) has a market capitalization of $595.76 million and generates $149.27 million in revenue each year. The biopharmaceutical company earns $560,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. How many employees does Avid Bioservices have? The company employs 365 workers across the globe. How can I contact Avid Bioservices? Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The official website for the company is www.avidbio.com. The biopharmaceutical company can be reached via phone at (714) 508-6100, via email at sdiaz@vidasp.com, or via fax at 714-838-5817. This page (NASDAQ:CDMO) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avid Bioservices, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.